Scholar Rock Holding (SRRK) Short-term Investments (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Short-term Investments of $49.4 million in Q1 2026, up 12.18% quarter-over-quarter from $44.0 million in Q4 2025, and down 78.18% on a YoY basis from $226.4 million in Q1 2025.
Scholar Rock Holding (SRRK) Short-term Investments (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Short-term Investments history runs 10 years deep, the most recent figure standing at $49.4 million for Q1 2026.
- In Q1 2026, Short-term Investments fell 78.18% year-over-year to $49.4 million; the TTM figure through Mar 2026 stood at $49.4 million (down 78.18% YoY), while the FY2025 annual figure was $44.0 million, down 83.02% from the prior year.
- Short-term Investments was $49.4 million for Q1 2026 at Scholar Rock Holding, up from $44.0 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $259.4 million in Q4 2024 to a low of $44.0 million in Q4 2025.
- Historically, Short-term Investments has averaged $135.4 million across 5 years, with a median of $140.7 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Short-term Investments surged 428.12% in 2022, then slumped 83.02% in 2025.
- A 5-year view of Short-term Investments shows it stood at $212.1 million in 2022, then declined by 16.03% to $178.1 million in 2023, then jumped by 45.66% to $259.4 million in 2024, then plunged by 83.02% to $44.0 million in 2025, then gained by 12.18% to $49.4 million in 2026.
- The last three Short-term Investments figures came in at $49.4 million (Q1 2026), $44.0 million (Q4 2025), and $82.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.40 Mn |
| Dec 31, 2025 | 44.04 Mn |
| Sep 30, 2025 | 82.86 Mn |
| Jun 30, 2025 | 142.09 Mn |
| Mar 31, 2025 | 226.45 Mn |
| Dec 31, 2024 | 259.40 Mn |
| Sep 30, 2024 | 62.67 Mn |
| Jun 30, 2024 | 97.12 Mn |
| Mar 31, 2024 | 146.45 Mn |
| Dec 31, 2023 | 178.08 Mn |
| Sep 30, 2023 | 151.04 Mn |
| Jun 30, 2023 | 140.67 Mn |
| Mar 31, 2023 | 124.00 Mn |
| Dec 31, 2022 | 212.09 Mn |
| Sep 30, 2022 | 210.58 Mn |
| Jun 30, 2022 | 64.96 Mn |
| Mar 31, 2022 | 110.04 Mn |
| Dec 31, 2021 | 40.16 Mn |
| Sep 30, 2021 | 70.30 Mn |
| Jun 30, 2021 | 75.30 Mn |